When people think about the cannabis industry, the conversation usually starts with CBD and THC. Appearing in everything from tinctures and capsules to skincare and beverages, these two compounds have dominated the plant-based wellness space.
The early CBD and THC boom is facing new pressures. Regulations are tightening, consumers are more informed and the broader wellness market is evolving.
As a result, companies that want to stay relevant are realising they can't rely on the same playbook forever. That shift requires an open mind and a willingness to adapt.
Regulators are beginning to look much more closely at hemp-derived products, particularly when it comes to THC limits, labelling requirements and product safety. In many ways, this scrutiny is a sign that the category is maturing.
At the same time, businesses that built their entire product line on CBD or THC are now finding themselves exposed to regulatory uncertainty and changing expectations. The companies most likely to thrive during the next five years will be those that are willing to change their approach.
Beyond THC
The cannabis plant itself has 113 different cannabinoids, many of which have barely been explored. Unlike traditional THC products, many minor compounds (such as CBG, CBN and THCV) offer functional effects without the intoxicating "high." Consumers are increasingly curious about targeted formulations that support sleep, focus or relaxation.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.
